Recommendation ID

Proposals for further data collection in the Cancer Drugs Fund include:
- recurrence-free survival
- distant metastases-free survival
- overall survival
- long-term follow-up of people who received pembrolizumab as an adjuvant treatment
- who develop advanced disease and receive pembrolizumab again to treat metastatic disease.

Any explanatory notes
(if applicable)


Source guidance details

Comes from guidance
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Date issued
December 2018

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   Yes  
Last Reviewed 31/12/2018